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D-BMAP18 antimicrobial peptide is active in vitro, resists to pulmonary proteases but loses its 
activity in a murine model of Pseudomonas aeruginosa lung infection. 
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In vivo acute toxicity of D-BMAP18 
Compared to control unexposed mice, exposure to peptide caused a significant (p<0.01) decrease in 
weight during the first 2 days regardless of doses used (Figure S1). This effect persisted until day 3 
p.e. when peptide was administered at 2, 4, and 8 mg/kg (p<0.05), and until day 4 p.e. at 4 and 8 
mg/kg (p<0.05). The reduction caused by exposure to peptide at 4 mg/kg persisted until day 5 p.e. 
(p<0.01). Mice started to gain their weight after day 2 p.e. regardless of doses administered, 
although they were not able to completely get the initial body weight until day 5 p.e.. Variations in 
pulmonary weight confirmed the same trend found for macroscopic score analysis (Figure S2). 
 
 
 
Figure S1. A) Changes in weight were graphed as the percentage of the body weight before single 
exposure to peptide. Results are shown as mean + SD values. Statistical analysis was carried out by 
ANOVA + Tukey’s multiple comparison post-test: **p<0.01, CTRL vs other groups; *p<0.05, 
CTRL vs (2, 4, and 8 mg/kg); °p<0.05, CTRL vs (4, and 8 mg/kg); °°p<0.01, CTRL vs 4 mg/kg. B) 
Lungs were removed en bloc from the chest via sterile excision, and immediately weighted. Results 
are shown as mean + SD values. *p<0.05, **p<0.01, ANOVA + Tukey’s multiple comparison post-
test. 
 
 
 
 
 
 
 
 
In vivo antimicrobial activity of D-BMAP18 
The lungs of mice treated with D-BMAP18 1 and 2 mg/kg were slightly more edematous, as 
suggested by the observed weight, compared to those administrated with tobramycin 10 mg/kg 
(Figure S2). 
 
Figure S2. C57BL/6NCrl lungs were weighted on day 1 following P. aeruginosa RP73 infection. 
Results are mean + SD. *p<0.05, ANOVA + Newman-Keuls multiple comparison post-test. 
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